AUS
NZ
UK
CA
USA
IND
Highlights
- Strategic Acquisition: GSK will pay $1 billion upfront, with an additional $150 million tied to regulatory approval milestones.
- Breakthrough Therapy Potential: IDRX-42 shows promising efficacy in addressing primary and secondary KIT mutations in GIST patients.
- Enhancing Treatment Options: Acquisition aims to address unmet needs in gastrointestinal stromal tumors (GIST) with IDRx’s cutting-edge technology.
GSK plc (LSE:GSK) has announced a definitive agreement to acquire IDRx, Inc., a Boston-based clinical-stage biopharmaceutical company specializing in precision therapeutics for gastrointestinal stromal tumors (GIST). The transaction, valued at up to $1.15 billion, includes a $1 billion upfront payment and a potential $150 million milestone payment contingent on regulatory approval.
At the heart of the acquisition is IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to target both primary and secondary KIT mutations that drive GIST. Current treatment options for GIST are limited, particularly for patients who develop resistance to first-line therapies due to secondary mutations. IDRX-42 has shown the potential to inhibit the full spectrum of KIT mutations, offering a promising new option for patients with this challenging condition.
Clinical Evidence Supports IDRX-42’s Potential
IDRX-42 has demonstrated encouraging results in StrateGIST 1, an ongoing Phase I/Ib trial evaluating its efficacy in patients with advanced GIST. Updated data presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting highlighted a 29% objective response rate (ORR) across all KIT mutation subsets in patients treated in the second line or later, with one complete response (CR) and 24 partial responses (PRs) observed among 87 evaluable patients.
Notably, in patients who had only one prior line of therapy, the ORR was even higher at 53%, including one CR and seven PRs. Emerging durability data suggest long-term efficacy, with IDRX-42 demonstrating a manageable safety profile. Most treatment-related adverse events (TRAEs) were low grade, supporting the drug’s potential for further clinical development.
Addressing an Unmet Medical Need
GIST primarily affects the gastrointestinal tract, with 80% of cases driven by mutations in the KIT gene that promote tumor growth and survival. Despite initial responses to treatment, approximately 90% of patients develop resistance due to secondary KIT mutations, leaving them with limited therapeutic options. Currently, there are no approved TKIs capable of targeting the full spectrum of KIT mutations.
By acquiring IDRx, GSK aims to accelerate the development of IDRX-42 and establish it as a first- and second-line therapy for GIST. The drug's high selectivity and comprehensive mutation coverage position it as a potential best-in-class treatment.
Financial Details
Under the agreement, GSK will acquire 100% of IDRx’s equity, including options and incentive shares, for a total cash consideration of $1.15 billion. This includes an upfront payment of $1 billion, with an additional $150 million linked to regulatory success milestones. GSK will also assume responsibility for milestone payments and tiered royalties owed to Merck KGaA, Darmstadt, Germany, for IDRX-42.
